Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Megan Barber

Clinical Cardiac Electrophysiology Bartlesville, OK Doctor of Osteopathy

NPI 1407274533 CMS profile 2793912

3460 E Frank Phillips Blvd, Bartlesville, OK 74006

Open in the dashboard

General payments

$17,481

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Megan Barber of Bartlesville, OK is reported in the CMS Open Payments database as having received $17,481 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $111 2
2024 General $451 5
2023 General $6,349 55
2022 General $4,278 34
2021 General $3,110 16
2020 General $2,797 13
2019 General $385 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Barber
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Megan Barber were reported at $111. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Megan Barber Clinical Cardiac Electrophysiology median Middle half National median
2019 $385 $2,361 $585–$8,260 $163
2020 $2,797 $993 $247–$4,351 $114
2021 $3,110 $1,185 $326–$4,739 $132
2022 $4,278 $2,073 $554–$6,789 $149
2023 $6,349 $2,568 $759–$8,159 $160
2024 $451 $2,557 $703–$7,403 $164
2025 $111 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,662 66 payments
  2. Biotronik Inc. $6,224 23 payments
  3. Medtronic Vascular, Inc. $1,463 15 payments
  4. Medical Device Business Services, Inc. $1,122 6 payments
  5. Philips Electronics North America Corporation $539 4 payments
  6. Boston Scientific Corporation $429 5 payments
  7. Abbott Laboratories $429 4 payments
  8. Biosense Webster, Inc. $393 5 payments
  9. Kestra Medical Technology Services, Inc. $109 2 payments
  10. Bard Peripheral Vascular, Inc. $78 1 payment
  11. Other $33 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $11,309 42 payments
  2. Food and Beverage $6,011 89 payments
  3. Education $162 1 payment
Products named General payments · program years 2019–2025
  1. Solia $3,771 15 payments
  2. BioMonitor $3,771 15 payments
  3. Rivacor $3,110 16 payments
  4. Edora $3,110 16 payments
  5. Acticor $3,110 16 payments
  6. Acticor 7 VR-T DX $1,432 2 payments
  7. Edora 8 DR-T $1,405 1 payment
  8. Rivacor 7 DR-T $1,405 1 payment
  9. Carto 3 $1,302 8 payments
  10. Sentus $743 2 payments
  11. Other $2,829 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

125

Median for Cardiology: 2,533

Drug cost

$39,875

Median for Cardiology: $485,213

Branded share of claims

37.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 47 $38,573
Metoprolol Succinate Generic 25 $590
Amiodarone Hcl Generic 18 $505
Mupirocin Generic 35 $207

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$71,041

Medicare's payments for the services billed

Medicare patients

705

Average age 76

Services billed

1,312

294 women, 411 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 56%
Ischemic heart disease 52%
Heart failure 51%
Chronic kidney disease 49%
Arthritis 39%
Diabetes 35%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record